Avantor (AVTR) Prices 20.83M Share Offering at $42/sh

Avantor, Inc. (NYSE: AVTR) today announced the pricing of the previously announced underwritten offering by the Company of 20,833,334 shares of its common stock pursuant to a registration statement filed by the Company with the U.S. Securities and Exchange Commission (the "SEC"), at the public offering price of $42.00 per share.

The Company has granted the underwriters a 30-day option to purchase up to an additional 2,976,190 shares of common stock on the same terms and conditions. The offering is expected to close on September 16, 2021, subject to customary closing conditions.

The Company intends to use the net proceeds from this offering, along with the proceeds from certain debt financing transactions, to finance its previously announced acquisition of the Masterflex bioprocessing business and related assets of Antylia Scientific. To the extent the acquisition is not consummated, the Company anticipates using the net proceeds of the offering for general corporate purposes.

Goldman Sachs & Co. LLC, Citigroup and BofA Securities are serving as the joint book-running managers and as representatives of the underwriters for the offering. Barclays is also serving as a bookrunner. Bancroft Capital, Centerview Partners, HSBC, PNC Capital Markets LLC, R. Seelaus & Co., LLC, RBC Capital Markets and Siebert Williams Shank are also acting as co-managers for the offering.

A registration statement relating to these securities has been filed with the SEC and has become effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The offering of these securities will be made only by means of a prospectus supplement and accompanying prospectus. Copies of the preliminary prospectus supplement and accompanying prospectus for the offering may be obtained from: Goldman Sachs & Co. LLC, Attention: Prospectus Department at 200 West Street, New York, NY 10282 or by telephone at 1-866-471-2526; Citigroup Global Markets Inc., Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone 1-800-831-9146 or by email at [email protected]; or BofA Securities, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte NC 28255-0001, Attn: Prospectus Department or by email at [email protected].

You May Also Be Interested In

• Intra-Cellular Therapies (ITCI) Announces Proposed $500M Share Offering
• APi Group Corporation (APG) Launches 11M Share Offering
• Cullinan Therapeutics (CGEM) Announces $280M Placement at $19/sh